Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) held its annual shareholder meeting on Thursday. Shareholders elected three Class I directors and approved key proposals.
Emil D. Kakkis, Shehnaaz Suliman, and Daniel G. Welch were elected to the board, serving until the 2029 meeting.
The 2023 Incentive Plan received 50,659,150 votes in favor. According to Bond.az analysis, the company is burning cash quickly.
Ernst & Young was ratified as the independent auditor. Shareholders also approved executive compensation in an advisory vote.
A total of 84,786,388 shares were represented. All information is based on the company's SEC filing.












